001     271104
005     20240818004533.0
024 7 _ |a pmid:38439203
|2 pmid
024 7 _ |a 10.1002/oby.23996
|2 doi
024 7 _ |a 1071-7323
|2 ISSN
024 7 _ |a 1930-7381
|2 ISSN
024 7 _ |a 1550-8528
|2 ISSN
024 7 _ |a 1930-739X
|2 ISSN
024 7 _ |a altmetric:160339370
|2 altmetric
037 _ _ |a DZNE-2024-00976
082 _ _ |a 610
100 1 _ |a Meroni, Marica
|b 0
245 _ _ |a Hepatic and adipose tissue transcriptome analysis highlights a commonly deregulated autophagic pathway in severe MASLD
260 _ _ |a Hoboken, NJ
|c 2024
|b Wiley
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1723628468_28438
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a The incidence of metabolic dysfunction-associated steatotic liver disease (MASLD) is rapidly ramping up due to the spread of obesity, which is characterized by expanded and dysfunctional visceral adipose tissue (VAT). Previous studies have investigated the hepatic transcriptome across MASLD, whereas few studies have focused on VAT.We performed RNA sequencing in 167 hepatic samples from patients with obesity and in a subset of 79 matched VAT samples. Circulating cathepsin D (CTSD), a lysosomal protease, was measured by ELISA, whereas the autophagy-lysosomal pathway was assessed by Western blot in hepatic and VAT samples (n = 20).Inflammation, extracellular matrix remodeling, and mitochondrial dysfunction were upregulated in severe MASLD in both tissues, whereas autophagy and oxidative phosphorylation were reduced. Tissue comparative analysis revealed 13 deregulated genes, including CTSD, which showed the most robust diagnostic accuracy in discriminating mild and severe MASLD. CTSD expression correlated with circulating protein, whose increase was further validated in 432 histologically characterized MASLD patients, showing a high accuracy in foreseeing severe liver injury. In addition, the assessment of serum CTSD increased the performance of fibrosis 4 in diagnosing advanced disease.By comparing the hepatic and VAT transcriptome during MASLD, we refined the concept by which CTSD may represent a potential biomarker of severe disease.
536 _ _ |a 354 - Disease Prevention and Healthy Aging (POF4-354)
|0 G:(DE-HGF)POF4-354
|c POF4-354
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, Journals: pub.dzne.de
700 1 _ |a De Caro, Emilia
|0 P:(DE-2719)9001921
|b 1
|u dzne
700 1 _ |a Chiappori, Federica
|b 2
700 1 _ |a Longo, Miriam
|b 3
700 1 _ |a Paolini, Erika
|b 4
700 1 _ |a Mosca, Ettore
|b 5
700 1 _ |a Merelli, Ivan
|b 6
700 1 _ |a Lombardi, Rosa
|b 7
700 1 _ |a Badiali, Sara
|b 8
700 1 _ |a Maggioni, Marco
|b 9
700 1 _ |a Orro, Alessandro
|b 10
700 1 _ |a Mezzelani, Alessandra
|b 11
700 1 _ |a Valenti, Luca
|b 12
700 1 _ |a Fracanzani, Anna Ludovica
|b 13
700 1 _ |a Dongiovanni, Paola
|0 0000-0003-4343-7213
|b 14
773 _ _ |a 10.1002/oby.23996
|g Vol. 32, no. 5, p. 923 - 937
|0 PERI:(DE-600)2027211-X
|n 5
|p 923 - 937
|t Obesity
|v 32
|y 2024
|x 1071-7323
856 4 _ |u https://pub.dzne.de/record/271104/files/DZNE-2024-00976%20SUP.zip
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/271104/files/DZNE-2024-00976.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/271104/files/DZNE-2024-00976.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:271104
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 1
|6 P:(DE-2719)9001921
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-354
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Disease Prevention and Healthy Aging
|x 0
914 1 _ |y 2024
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2023-10-24
915 _ _ |a Creative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND 4.0
|0 LIC:(DE-HGF)CCBYNCND4
|2 HGFVOC
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b OBESITY : 2022
|d 2023-10-24
915 _ _ |a DEAL Wiley
|0 StatID:(DE-HGF)3001
|2 StatID
|d 2023-10-24
|w ger
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-10-24
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b OBESITY : 2022
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-10-24
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-10-24
920 1 _ |0 I:(DE-2719)5000082
|k AG Aschenbrenner
|l Aging and Immunity
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)5000082
980 1 _ |a FullTexts


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21